CMP: $95

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.

Alexion Pharmaceuticals is a $18 Billion market cap company trading at a P/E of 84. Revenues have risen from $386 Million to $783 Million in the last 2 years. Profits have dipped from $295 Million to $175 Million in the last 2 years. Profit margins have dipped from 75% to 22% in the last 2 years. At a high P/E, its a high risk investment. But, Zero long term debt and revenue growth looks promising.